Qualification is usually fact-specific and depends on the timeline of use, symptom onset, testing results, and individual risk factors, including other health conditions and medications
I built this matrix by mapping each row to the single trial endpoint that produced the highest-quality primary evidence as of mid-2026: percent body-weight change for efficacy (Jastreboff 2023, SURMOUNT-1, STEP 1), three-point MACE for cardiovascular (SELECT), MRI-PDFF for hepatic fat (retatrutide Phase 2 sub-analyses, [unverified primary source]), and treatment-emergent adverse event rates for GI burden
Y., Yazici, D., Pizzagalli, D
Retatrutide is generally well-tolerated, but its not suitable for everyone
2024;31(4):e523e527
TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial